Skip to main content
TIBET AIM PHARM. INC. logo

TIBET AIM PHARM. INC. — Investor Relations & Filings

Ticker · 002826 ISIN · CNE100002C39 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,085 across all filing types
Latest filing 2016-11-20 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 002826

About TIBET AIM PHARM. INC.

https://www.emyy.cn

Tibet Aim Pharm. Inc. is a pharmaceutical enterprise focused on the research, development, production, and distribution of medicinal products. The company integrates traditional Tibetan medicine with modern pharmaceutical manufacturing processes to develop a diverse portfolio of treatments. Its core product range typically includes cardiovascular medications, digestive system therapies, and specialized herbal formulations derived from high-altitude botanical sources. Tibet Aim Pharm. Inc. emphasizes the modernization of traditional formulas through rigorous clinical testing and standardized production techniques. The company serves healthcare providers and patients by providing therapeutic solutions that bridge ancient medical knowledge with contemporary scientific standards.

Recent filings

Filing Released Lang Actions
首次公开发行股票投资风险特别公告
Capital/Financing Update Classification · 95% confidence The document is titled as a "首次公开发行股票投资风险特别公告" which translates to "Special Announcement on Investment Risks for Initial Public Offering (IPO)". It discusses the details of the IPO including the number of shares, pricing, subscription process, underwriting, and associated investment risks. It references regulatory approval by the China Securities Regulatory Commission and provides detailed instructions and risk disclosures for investors. The document is not a financial report, earnings release, or management discussion but rather a formal announcement related to the capital raising process and associated risks. It does not contain financial statements or detailed financial analysis but focuses on the IPO issuance and investment risk disclosure. Therefore, it fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities such as IPOs.
2016-11-20 Chinese
首次公开发行股票发行公告
Capital/Financing Update Classification · 100% confidence The document is a detailed announcement regarding the initial public offering (IPO) of shares by 西藏易明西雅医药科技股份有限公司. It includes information about the issuance scale, pricing, subscription procedures, underwriting, allotment, and payment instructions. The document references regulatory approvals, pricing mechanisms, investor eligibility, and subscription timelines. It is not a financial report, earnings release, or management discussion but rather a formal announcement of a capital raising event through stock issuance. This fits the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes.
2016-11-20 Chinese
首次公开发行股票网上路演公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the initial public offering (IPO) of shares by 西藏易明西雅医药科技股份有限公司. It details the number of shares to be issued, the approval by the China Securities Regulatory Commission, the method of issuance (offline inquiry and online subscription), and the schedule for an online roadshow to inform investors about the offering. The document does not contain financial statements or detailed financial performance data, nor is it a transcript or report of a meeting. It is an announcement related to capital raising activities, specifically the IPO process and investor presentation event. Therefore, the most appropriate classification is 'Capital/Financing Update' (CAP). The document length is short and it is not merely announcing the publication of a report but providing substantive information about the offering and roadshow.
2016-11-17 Chinese
首次公开发行股票招股意向书摘要
Share Issue/Capital Change Classification · 95% confidence The document is titled as a "首次公开发行股票招股意向书摘要" which translates to "Summary of Prospectus for Initial Public Offering (IPO)". It contains detailed information about the IPO, including shareholder lock-up commitments, dividend policies, profit distribution, shareholding intentions, stock price stabilization plans, and various legal and financial commitments related to the IPO process. The document is not a financial report like an annual or quarterly report, nor is it a simple announcement or certification. It is a detailed prospectus summary related to the issuance of new shares to the public. This type of document fits best under the category of Share Issue/Capital Change (SHA), as it relates to the issuance of new shares and capital raising activities.
2016-11-13 Chinese
首次公开发行股票初步询价及推介公告
Capital/Financing Update Classification · 100% confidence The document is a detailed announcement regarding the initial public offering (IPO) of shares by 西藏易明西雅医药科技股份有限公司. It includes information about the preliminary inquiry, pricing, investor qualifications, subscription procedures, allotment mechanisms, and important dates related to the IPO process. The text references regulatory bodies such as the China Securities Regulatory Commission and Shenzhen Stock Exchange, and discusses the issuance of new shares, subscription timelines, and investor obligations. It is not a financial report, earnings release, or management discussion, but rather a formal announcement about the IPO process and related subscription and pricing details. Therefore, this document fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities such as IPOs.
2016-11-13 Chinese
北京国枫律师事务所关于公司申请首次公开发行股票并上市的补充法律意见书之二
Regulatory Filings
2016-11-13 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.